Chemesis Subsidiary, GSRX, Files Interim Financial Statements
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
Chemesis Subsidiary, GSRX, Files Interim Financial Statements
September 20, 2019
Vancouver, BC – Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or
“Chemesis”), announces that its subsidiary , GSRX Industries Inc. (“ GSRX”) ( OTCQB: GSRX ), filed its
interim financial statements for the six months ended June 30, 2019 (“GSRX Financial Statements”).
Highlights from the GSRX Financial Statements include:
● Highest revenues of any quarter to date with $3.4M USD for the three months ended June
30, 2019; and
● Gross profit of $1.34M USD, and a gross margin of 39%;
● A summary of key operational revenue and expenses comparing quarter over quarter
(“QOQ”) and year over year (“YOY”) are summarized below:
(Prepared in accordance with U.S. GAAP.)
GSRX operational results show significant growth in revenues while maintaining tight control over its
operational spending. This growth was primarily achieved through its retail business’ in Puerto Rico,
California, Texas, and Tennessee. GSRX currently operates six dispensaries and two retail CBD stores, as
well as five pre-qualified dispensaries in Puerto Rico that are in various stages of development . It also
has a dispensary in Palm Springs, California.
On August 29, 2019 Chemesis announced that it had acquired a controlling interest in GSRX . Chemesis
will begin co nsolidating the financial statements of GSRX within its own financial statements from the
date of the acquisition. The Company notes that Board of Directors of GSRX is comprised of Aman
Parmar, Christian Briggs, Mike Aujla, Les Ball, and Edgar Montero, wi th Messrs. Parmar and Briggs
serving as co-Chairmen.
GSRX’s 10 -Q quarterly report for the six months ended June 30, 2019 is available on EDGAR and
available at www.sec.gov.
Chemesis’ year-end audited financial statements for the year ended June 30, 2019 will be filed before its
% QOQ % YOY
Q2 2019 Q1 2019 Change Q2 2018 Change
$ $ $
Revenues 3,439,225 2,866,079 20% 353,430 873%
Consulting Fees 413,707 453,029 (9%) 357,990 16%
General & Administrative 1,478,002 1,755,354 (16%) 1,138,396 30%
Professional Fees 212,558 335,475 (37%) 134,464 58%
Loss from Operations (924,024) (3,238,324) (71%) (3,656,238) (75%)
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
deadline of October 28, 2019.
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently
operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution
and retail. Chemesis has facilit ies in both Puerto Rico and California, allowing for cost effective
production and distribution of its products. In addition, Chemesis leverages exclusive brands and
partnerships and uses the highest quality extraction methods to provide consumers with qua lity
cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently
delivering quality product to its consumers from seed to sale.
Investor Relations:
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "fo rward-looking information" within the meaning of
applicable securities laws , including in regard to the business, profitability, products and future of the Company’s
business, its product offerings and plans for revenue generation, sales and marketing. Although the Company
believes that the expectations reflected in the forward -looking information are reasonable, there can be no
assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on
forward-looking information. Such forward -looking statements are subject to risks and uncertainties that may
cause actual results, performance and developments to differ materially from those contemplated by these
statements depending on, among other things, t he risks that the Company's products and plan will vary from those
stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation and does n ot intend to update any forward -
looking statements or forward -looking information in this news release. Although the Company believes that the
expectations reflected in the forward -looking information are reasonable, there can be no assurance that such
expectations will prove to be correct and makes no reference to profitability based on sales reported. The
statements in this news release are made as of the date of this release.
Chemesis, Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA)
The CSE has not reviewed, approved or disapproved the content of this press release